- Home
- GHI vs HURA Comparison
GHI vs HURA Comparison
Compare GHI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Company Overview
Basic Information| Metric | GHI | HURA |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.3M | 123.0M |
| IPO Year | 1998 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GHI | HURA |
|---|---|---|
| Price | $4.12 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 90.9K | ★ 436.1K |
| Earning Date | 11-09-2026 | 11-24-2026 |
| Dividend Yield | ★ 13.46% | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,389,766.00 | N/A |
| Revenue This Year | $236.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.91 | $0.41 |
| 52 Week High | $8.16 | $3.43 |
Technical Indicators
Market Signals| Indicator | GHI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 33.27 |
| Support Level | N/A | $1.27 |
| Resistance Level | $5.45 | $1.55 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 19.17 | 7.56 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.